Norberto C. Chávez-Tapia

Emerging pharmacological treatment options for MASLD/MASH

The prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) has risen substantially over recent decades, affecting an estimated 38% of the global population. It has become a leading cause of liver disease, with the potential to progress to steatohepatitis (MASH), fibrosis, and ultimately cirrhosi...